ArticleNature biotechnology2016
An injectable nanoparticle generator enhances delivery of cancer therapeutics.
Article in Nature biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed.
- Physicochemical design of nanobiomaterials in oncology: structure-to-function principles for sequential transport and delivery.Frontiers in oncology · 2026Review
- Article
- Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm.Biomaterials · 2025Article
- GSH/pH-responsive copper-based cascade nanocomplexes inducing immunogenic cell death through cuproptosis/ferroptosis/necroptosis in oral squamous cell carcinoma.Materials today. Bio · 2025Article
- Recent advances in the bench-to-bedside translation of cancer nanomedicines.Acta pharmaceutica Sinica. B · 2025Review
- Nanotheranostics: The Fabrication of Theranostics with Nanoparticles and their Application to Treat the Neurological Disorders.Recent patents on nanotechnology · 2025Review
- Advances in nanomedicine and delivery systems for gastric cancer research.Frontiers in bioengineering and biotechnology · 2025Review
- Biomimetic nanocarriers in cancer therapy: based on intercellular and cell-tumor microenvironment communication.Journal of nanobiotechnology · 2024Review
- Review
- Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2023Review
- Near-infrared light-responsive Nitric oxide microcarrier for multimodal tumor therapy.Smart medicine · 2023Article
- Boosting the Potential of Chemotherapy in Advanced Breast Cancer Lung Metastasis via Micro-Combinatorial Hydrogel Particles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer.Beilstein journal of nanotechnology · 2023Review
- Quantitative Analysis of Porous Silicon Nanoparticles Functionalization byACS biomaterials science & engineering · 2022Article
- CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- Syntheses of Polypeptides and Their Biomedical Application for Anti-Tumor Drug Delivery.International journal of molecular sciences · 2022Review
- Versatile activity and morphological effects of zinc oxide submicron particles as anticancer agents.Nanomedicine (London, England) · 2022Article
- Review
- Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects.Theranostics · 2022Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
Abstract
The efficacy of cancer drugs is often limited because only a small fraction of the administered dose accumulates in tumors. Here we report an injectable nanoparticle generator (iNPG) that overcomes multiple biological barriers to cancer drug delivery. The iNPG is a discoidal micrometer-sized particle that can be loaded with chemotherapeutics. We conjugate doxorubicin to poly(L-glutamic acid) by means of a pH-sensitive cleavable linker, and load the polymeric drug (pDox) into iNPG to assemble iNPG-pDox. Once released from iNPG, pDox spontaneously forms nanometer-sized particles in aqueous solution. Intravenously injected iNPG-pDox accumulates at tumors due to natural tropism and enhanced vascular dynamics and releases pDox nanoparticles that are internalized by tumor cells. Intracellularly, pDox nanoparticles are transported to the perinuclear region and cleaved into Dox, thereby avoiding excretion by drug efflux pumps. Compared to its individual components or current therapeutic formulations, iNPG-pDox shows enhanced efficacy in MDA-MB-231 and 4T1 mouse models of metastatic breast cancer, including functional cures in 40-50% of treated mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.